PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: Systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Mo, Chen ^a,b   Sun, Gang ^a   Wang, Yan Zhi ^a   Lu, Ming Liang ^a   Yang, Yun Sheng ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Chinese People's Armed Police Force General Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ANTIULCER AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; DIGESTIVE SYSTEM ULCER; HUMAN; LOW DRUG DOSE; META ANALYSIS; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UPPER GASTROINTESTINAL BLEEDING; CHEMICALLY INDUCED; DRUG EFFECTS; GASTROINTESTINAL DISEASES; HEMORRHAGE; UPPER GASTROINTESTINAL TRACT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ASPIRIN; GASTROINTESTINAL DISEASES; HEMORRHAGE; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UPPER GASTROINTESTINAL TRACT;

EID: 84940044431     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131558     Document Type: Article

References (61)

1. Luk HH. Use of gastroprotective drugs in patients receiving low-dose aspirin. J Chin Med Assoc.2009; 72: 356-361. doi: 10.1016/S1726-4901(09)70387-9 PMID: 19581141
2. Zhu LL, Xu LC, Chen Y, Zhou Q, Zeng S. Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications. World J Gastroenterol.2012; 18: 3167-3172. doi: 10.3748/wjg.v18.i24.3167 PMID: 22791953
3. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med.2002; 346: 2033-2038. PMID: 12087138
4. Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Racz I, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol.2008; 103: 2465-2473. doi: 10.1111/j.1572-0241.2008.01995.x PMID: 18637091
5. Sugano K, Matsumoto Y, Itabashi T, Abe S, Sakaki N, Ashida K, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol.2011; 46: 724-735. doi: 10.1007/s00535-011-0397-7 PMID: 21499703
6. Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart.2011; 97: 797-802. doi: 10.1136/hrt.2010.217547 PMID: 21415072
7. Sanuki T, Fujita T, Kutsumi H, Hayakumo T, Yoshida S, Inokuchi H, et al. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. J Gastroenterol.2012; 47: 1186-1197. doi: 10.1007/s00535-012-0588-x PMID: 22526273
8. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ.2008; 7634:2-3.
9. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007; 5: 1418-1423. PMID: 18054750
10. Ramsay EN, Pratt NL, Ryan P, Roughead EE. Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs. BMC Med Res Methodol.2013; 13: 82. doi: 10.1186/1471-2288-13-82 PMID: 23800078
11. Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Reserch Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013; 24: 1161-1168. doi: 10.1007/s00198-012-2112-9 PMID: 22890365
12. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374: 119-125. doi: 10.1016/S0140-6736(09)61246-0 PMID: 19577798
13. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002; 4: CD002296. PMID: 12519573
14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 21: b2700.
15. Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011; 141: 71-79. doi: 10.1053/j.gastro.2011.03.049 PMID: 21458456
16. Yasuda H, Yamada M, Sawada S, Endo Y, Inoue K, Asano F et al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Intern Med. 2009; 48: 1725-1730. PMID: 19797827
17. Tamura A, Murakami K, Kadota J. Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2. BMC Res Notes. 2013; 6: 1756-0500.
18. Nakashima S, Ota S, Arai S, Yoshino K, Inao M, Ishikawa K et al. Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. World J Gastroenterol. 2009; 15: 727-731. PMID: 19222098
19. Wu CY, Chan FK, Wu MS, Kuo KN, Wang CB, Tsao CR et al. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology. 2010; 139: 1165-1171. doi: 10.1053/j.gastro.2010.06.067 PMID: 20600012
20. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Bujanda L, Gomollon F, Forne M et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007; 102: 507-515. PMID: 17338735
21. Wang Z, Yang XC, Cai J, Chen ML, Wan XH. Proton pump inhibitors on the antiplatelet function of clopidogrel after coronary artery intervention treatment of acute myocardial infarction patients. Chinese Journal of Medicine. 2013; 48: 20-22.
22. Tian XX, Du H, Zheng YF, Zhou Q, Zhang Y, Bai YL. Esomeprazole Combined with Rebamipide in Preventing Gastric Mucosal Lesions Induced by Non-steroidal Anti-inflammatory Drugs. Chin Gen Pract. 2013; 16: 2407-2409.
23. Du Y, Wang M, Pan JS. Analysis of acid-suppressive drug choice after PCI in patients with coronary heart diseases. Chin New Drug J. 2013; 22: 975-982.
24. Ji CY, Wang Y, Tan SY, Liu H. Efficacy of esomeprazole on gastrointestinal bleeding caused by NSAIDs in the eldery. Pract Geriatr. 2011; 25: 128-130.
25. Wang Y. Effect of different proton pump inhibitors or H2 receptor antagonists on the anti-platelet functions of clopidogrel in patients after PCI. Thesis, Fourth Military Medical University. 2012.
26. Wu G. Effect of prognosis of patients with proton pump inhibitors after percutaneous coronary intervention treatment: A retrospective analysis. Thesis, Guang Xi Medical University. 2012.
27. Nema H, Kato M. Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. World J Gastroenterol. 2010; 16: 5342-5346. PMID: 21072898
28. Sakurada T, Kawashima J, Ariyama S, Kani K, Takabayashi H, Ohno S et al. Comparison of adjuvant therapies by an H2-receptor antagonist and a proton pump inhibitor after endoscopic treatment in hemostatic management of bleeding gastroduodenal ulcers. Dig Endosc. 2012; 24: 93-99. doi: 10.1111/j.1443-1661.2011.01176.x PMID: 22348833
29. Sakurai K, Nagahara A, Inoue K, Akiyama J, Mabe K, Suzuki J et al. Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS). BMC Gastroenterol. 2012; 12: 12-42.
30. Tanaka S, Nishigaki K, Ojio S, Okubo M, Yasuda S, Ishihara Y et al. Can negative cardiac effect of proton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stable angina? J Cardiol. 2008; 52: 39-48. doi: 10.1016/j.jjcc.2008.05.004 PMID: 18639776
31. Sener-Muratoglu G, Paskaloglu K, Arbak S, Hurdag C, Ayanoglu-Dulger G. Protective effect of famotidine, omeprazole, and melatonin against acetylsalicylic acid-induced gastric damage in rats. Dig Dis Sci. 2001; 46: 318-330. PMID: 11281181
32. Cao YZ, Liu L, Wang BL, Lu J, He BJ, Zhong YX, et al. PPI vs H2A-Which is stronger inhibitor on acute peptic ulcer bleeding. J Fourth Mil Med Univ. 2001; 22: 790-792.
33. Li M. High dose proton pump inhibitor and H2 receptor antagonist in the therapy of 86 upper gastrointestinal bleeding patients. Cli Med. 2011; 31:56-57.
34. Brophy GM, Brackbill ML, Bidwell KL, Brophy DF. Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients. Neurocrit Care. 2010; 13: 176-181. doi: 10.1007/s12028-010-9397-3 PMID: 20596795
35. Kim YJ, Cheon JH, Lee SK, Kim JH, Lee YC. Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study. J Korean Med Sci. 2010; 25: 583-588. doi: 10.3346/jkms.2010.25.4.583 PMID: 20358002
36. Furuta T, Shirai N, Sugimoto M, Nakamura A, Okudaira K, Kajimura M et al. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Aliment Pharmacol Ther. 2005; 22: 67-74. PMID: 15963082
37. Arbel Y, Birati EY, Finkelstein A, Halkin A, Kletzel H, Abramowitz Y et al. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study. Clin Cardiol. 2013; 36: 342-346. doi: 10.1002/clc.22117 PMID: 23630016
38. Nagata Y, Inomata J, Kinoshita M, Kurokawa K, Aburadani I, Maruyama M et al. Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in Japanese patients. Cardiovasc Interv Ther. 2013; 28: 22-29. doi: 10.1007/s12928-012-0123-2 PMID: 22886368
39. Tunggal P, Ng FH, Lam KF, Chan FK, Lau YK. Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. Am Heart J. 2011; 162: 870-874. doi: 10.1016/j.ahj.2011.08.007 PMID: 22093203
40. Li Y, Wang ZR. Comparison of famotidine and rabeprazole on anti-platelet function of clopidogrel in patients with coronary stenting. Shaanxi Med J. 2013; 42: 1186-1188.
41. Nishino M, Sugimoto M, Kodaira C, Yamade M, Uotani T, Shirai N et al. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. J Clin Pharmacol. 2011; 51: 1079-1086. doi: 10.1177/0091270010376194 PMID: 20663999
42. Tolbert K, Bissett S, King A, Davidson G, Papich M, Peters E et al. Efficacy of oral famotidine and 2 omeprazole formulations for the control of intragastric pH in dogs. J Vet Intern Med. 2011; 25: 47-54. doi: 10.1111/j.1939-1676.2010.0651.x PMID: 21143305
43. Takahashi Y, Amano Y, Yuki T, Ose T, Miyake T, Kushiyama Y et al. Influence of acid suppressants on gastric emptying: cross-over analysis in healthy volunteers. J Gastroenterol Hepatol. 2006; 21: 1664-1668. PMID: 16984586
44. Bersenas AM, Mathews KA, Allen DG, Conlon PD. Effects of ranitidine, famotidine, pantoprazole, and omeprazole on intragastric pH in dogs. Am J Vet Res. 2005; 66: 425-431. PMID: 15822586
45. Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA et al. Effect of gastric acid suppressants on human gastric motility. Gut. 1998; 42: 243-250. PMID: 9536950
46. Iida H, Inamori M, Akimoto K, Mawatari H, Endo H, Nozaki Y et al. Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH. Hepatogastroenterology. 2009; 56: 551-554. PMID: 19579641
47. Sakaguchi M, Ashida K, Umegaki E, Miyoshi H, Katsu K. Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. J Clin Gastroenterol. 1995; 20: S27-31. PMID: 7594334
48. Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, et al. Famotidine Is Inferior to Pantoprazole in Preventing Recurrence of Aspirin-Related Peptic Ulcers or Erosions. Gastroenterology.2010; 138: 82-88. doi: 10.1053/j.gastro.2009.09.063 PMID: 19837071
49. Ng FH, Tunggal P, Chu WM, Lam KF, Li A, Chan K, et al. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol.2012; 107: 389-396. doi: 10.1038/ajg.2011.385 PMID: 22108447
50. Yano H, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, et al. Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. Circ J.2012; 76: 2673-2680. PMID: 22864179
51. Guo M, Wang J, Zou YC, Weng Y. The clinical effect of esomeprazole in prevention of low dose aspirin induced gastric mucosal injury. Chin J Dig.2009; 29: 481-482.
52. Sun RR, He YQ, Li R. The effect of rabeprazole in prevention of low-dose aspirin induced gastric mucosal injury in 40 elder patients. Chin J Mod Drug. 2012; Appl 06: 79-80.
53. Wang YP, Wang RJ. The clinical effect of lansoprazole in prevention of low dose aspirin induced gastric mucosal injury. Strait Pharm J 24:114-115.
54. Hu L, Zhou T, Xia YH. (2012) The effect of rabeprazole in prevention of low dose aspirin induced gastric mucosal injury. MMJC. 2012; 14:100-101.
55. Lu BJ, Qiao YJ, Yin YD. Omeprazole affects antiplatelet efficacy of clopidogrel and aspirin after intervention therapy. Chin J Prac Med. 2013; 40: 87-88.
56. Wang J, Zhou GK, Guo M, Zou YC, Wang MX. The efficacy in prevention of upper gastrointestinal injury in patients of acute coronary syndrome with esomeprazole. Chin J Card Res. 2012; 10: 191-195.
57. Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol.2011; 9: 762-768. doi: 10.1016/j.cgh.2011.05.020 PMID: 21699808
58. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010; 122: 2619-2633. doi: 10.1161/CIR.0b013e318202f701 PMID: 21060077
59. Tamura A, Murakami K, Kadota J. Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2. BMC Res Notes. 2013; 6: 1756-0500.
60. Ng FH, Lam KF, Wong SY, Chang CM, Lau YK, Yuen WC, et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion. 2008; 77: 173-177. doi: 10.1159/000141264 PMID: 18577887
61. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther.2002; 16: 779-786. PMID: 11929396